Latest Conference Articles

The results show melatonin levels or phases relative to clock time were not different between healthy individuals and patients with obstructive sleep apnea.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Within the reactive care gout conversations, “pain” and “swelling” were significantly more likely to be mentioned when compared with proactive care conversations.

Between 2000 and 2019, age-standardized incidence rates of autoimmune diseases increased by 4%.

Adverse events were significantly more frequently reported by pregnant patients when compared with non-pregnant patients. However, no differences were observed when comparing pregnant patients with autoimmune disease and healthy controls.

Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.

The results of the study provide a proof of concept for upadacitinib treatment in patients with systemic lupus erythematosus.

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort.

Data indicate dazodalibep has the potential to address unmet therapeutic needs for patients with Sjögren’s syndrome.

Late-breaking data from ATS 2023 show new positive evidence of the innovative in-vitro diagnostic tool IntelliSep test that measures the viscoelastic properties of leukocytes, showing promising results for rapid sepsis diagnosis in EDs.

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.

At ATS 2023, Dr. Galiatsatos illuminates what makes lung cancer screening different and how the screening approach is changing.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

A post hoc analysis shows benralizumab was even more efficacious in patients with concomitant nasal polyps at both 6 and 12 months.

Dr. Panagis Galiatsatos explains the new lung cancer screening aims to address the disparities of disease onset and progression across different racial populations.

Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.

An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

Unlike other screenings, lung cancer screening is new and patients need to know what happens next, according to Dr. Panagis Galiatsatos.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

Promising results from the ATS Conference suggest that AD109, an oral treatment for obstructive sleep apnea, demonstrated significant reduction of AHI and potential mitigation of daytime fatigue.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.